AI Article Synopsis
- The rise in multiresistant gram-negative bacteria has led to increased use of carbapenems, but there is limited data on meropenem's pharmacokinetics in patients undergoing peritoneal dialysis (PD).
- Researchers studied the effects of repeated intraperitoneal administration of meropenem for 21 days in treating polymicrobial multiresistant PD-related peritonitis.
- Findings suggest that a daily dose of 125 mg/L meropenem is both effective and safe, with no signs of drug overdosing or underdosing observed during the treatment period.
Article Abstract
With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis.Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033637 | PMC |
| http://dx.doi.org/10.3747/pdi.2016.00023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!